Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-15 EDT			5-day change	1st Jan Change
41.7 ^TWD	0.00%		+0.24%	-18.07%

03-20	Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	CI
03-14	Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 06:05 am

Senhwa Biosciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 1 million compared to TWD 0.55 million a year ago. Net loss was TWD 349.63 million compared to TWD 329.26 million a year ago.

Basic loss per share from continuing operations was TWD 3.92 compared to TWD 3.67 a year ago. Diluted loss per share from continuing operations was TWD 3.92 compared to TWD 3.67 a year ago.

Latest news about Senhwa Biosciences, Inc.

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	03-20	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19	01-05	CI
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	12-26	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	11-09	CI
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	23-10-19	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19	23-04-28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer	22-10-31	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC	22-06-06	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting	22-03-28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
US FDA Grants Fast Track Designation to Senhwa Biosciences' Cancer Drug	22-01-26	MT
Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations	22-01-25	CI
Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2	22-01-20	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference	21-10-20	CI
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference	21-09-27	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations	21-09-10	CI

Chart Senhwa Biosciences, Inc.

Duration

Period

More charts

Company Profile

Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

	1st Jan change	Capi.
SENHWA BIOSCIENCES, INC.	-18.07%	116M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs